Allos Therapeutics Announces Public Offering of 9,000,000 Shares of Common Stock
19 Mai 2008 - 12:41PM
Business Wire
Allos Therapeutics, Inc. (Nasdaq:ALTH) announced today that it is
offering to sell, subject to market and other conditions, 9,000,000
shares of newly issued common stock in an underwritten public
offering. In connection with the offering, the Company expects to
grant the underwriters a 30-day option to purchase an additional
1,350,000 shares of common stock from the Company to cover
overallotments. The Company plans to use the net proceeds from the
financing primarily for clinical and preclinical research and
development of its product candidates, manufacture of clinical
trial material and pre-commercial scale-up activities for PDX,
working capital and general corporate purposes. Merrill Lynch &
Co. is acting as sole bookrunner for this offering. Banc of America
Securities LLC and Citigroup Global Markets Inc. are acting as
co-lead managers. Information about the offering is available in
the prospectus supplement filed with the Securities and Exchange
Commission. Copies of the prospectus supplement may be obtained
from Merrill Lynch & Co., by mail at Merrill Lynch's prospectus
department at 4 World Financial Center, New York, NY 10080. The
shares will be issued pursuant to a shelf registration statement
filed with the Securities and Commission on May 23, 2007 and
declared effective on June 5, 2007. This press release does not and
shall not constitute an offer to sell or the solicitation of an
offer to buy the Company's common stock, nor shall there be any
sale of the common stock in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any
state. Any offer, if at all, will be made only by means of a
prospectus, including a prospectus supplement, forming a part of
the effective shelf registration statement. About Allos
Therapeutics, Inc. Allos Therapeutics is a biopharmaceutical
company focused on developing and commercializing small molecule
therapeutics for the treatment of cancer.�The Company's lead
product candidate, PDX (pralatrexate), is a novel antifolate
currently under evaluation in a pivotal Phase 2 (PROPEL) trial in
patients with relapsed or refractory peripheral T-cell lymphoma.
The PROPEL trial is being conducted under an agreement reached with
the U.S. Food and Drug Administration under its special protocol
assessment, or SPA, process. The Company is also investigating PDX
in patients with non-small cell lung cancer and a range of lymphoma
sub-types. The Company's other product candidate�is RH1, a targeted
chemotherapeutic agent currently being evaluated in a Phase 1 trial
in patients with advanced solid tumors or non-Hodgkin�s lymphoma
(NHL). For additional information, please visit the Company�s
website at www.allos.com. Safe Harbor Statement This press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements include statements
concerning the completion of the proposed financing, the potential
to complete our ongoing development programs with the proceeds of
the financing, and other statements which are other than statements
of historical facts. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "expects," "intends," "plans," anticipates," "believes,"
"estimates," "predicts," "projects," "potential," "continue," and
other similar terminology or the negative of these terms, but their
absence does not mean that a particular statement is not
forward-looking. Such forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties
that may cause actual results to differ materially from those
anticipated by the forward-looking statements. These risks and
uncertainties include, among others: the risk that the financing
may be delayed or may not occur due to market or other conditions
and the risk that additional capital may be required in the future
to complete on-going trials. Additional information concerning
these and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2007, the
Company's other periodic reports and filings with the SEC and the
prospectus supplement related to the proposed offering filed with
the SEC on May 19, 2008. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024